Cholesterol levels in patients with multiple myeloma

Annals of Hematology

Volumn 87, Issue 3, 2008, Pages 223-228

  Yavasoglu, Irfan ^a   Tombuloglu, Murat ^b   Kadikoylu, Gurhan ^a   Donmez, Ayhan ^b   Cagırgan, Seckin ^b   Bolaman, Zahit ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cholesterol levels; Multiple myeloma

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPOCHOLESTEROLEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 38649119133     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0375-6     Document Type: Article

References (40)

1. Castelli WP (1984) Epidemiology of coronary heart disease. The Framingham study. Am J Med 76:4-12
2. Ginsberg HN, Goldberg IJ (1998) Disorders of lipoprotein metabolism. In: Fauci SA, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper LD, Hauser LS, Longo LD (eds) Harrison's principles internal medicine, 14st edn. Mcgraw-Hill, New York, pp 2138-2149
3. Muller G, Schilf K (1987) Hypocholestreolemia. Z Gesamte Inn Med 42:310-313 (Abstract)
4. Tomiki Y, Suda S, Tanaka M, Okuzawa A, Matsuda M, Ishibiki Y, Sakamato K, Kamano T, Tsurumaru M, Watanabe Y (2004) Reduced low-density-lipoprotein cholesterol causing low serum cholesterol levels in gastrointestinal cancer: A case control study. J Exp Clin Cancer Res 23:233-240
5. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H (2000) Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med 5:201-205
6. Gadomska H, Janecki J, Marianowski L, Nowicka G (1997) Lipids in serum of patients with malignant ovarian neoplasms. Int J Gynaecol Obstet 57:287-293
7. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA (1983) The dual role of mevalonate in cell cycle. J Biol Chem 258:378-385
8. Gal D, Ottashi M, Macdonald PC, Buschbaum HJ, Simpson ER (1981) Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139:877-885
9. Niendorf A, Nagele H, Gerding D, Meyer-Pannwitt U, Gebhardt A (1995) Increased LDL receptor mRNA expression in colon cancer is correlated with rise in plasma cholesterol levels after curative surgery. Int J Cancer 6:461-464
10. Vassiliou G, Benoist F, Lau P, Kavaslar GN, Mcpherson P (2001) The low density lipoprotein receptor-related protein contributes to selective uptake of HDL-cholesteryl esters by Sw872 liposarcoma cells and primary human adipocytes. J Biol Chem 276:48823-48830
11. Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, Skoog L (1985) Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2:143-147
12. Allampallam K, Dutt D, Nair C, Shetty V, Mundle S, Lisak L, Andrews C, Ahmed B, Mazzone L, Zorat F, Borok R, Muzammil M, Gundroo A, Ansaarie I, Raza A (2000) The clinical and biological significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cells 9:247-255
13. Goncalves RP, Rodrigues DG, Maranhao RC (2005) Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res 29:955-959
14. Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997) Hypocholesterolemia in hairy cell leukemia: A marker for proliferative activity. Am J Hematol 55:129-133
15. Musolino C, Calabro L, Bellomo G, Cincotta M, Di Giacomo V, Pezzano C, Loteta B, Rizzo B, Guglielmo S, Alonci A (2002) Lipid profile in hematologic neoplasms. Recenti Prog Med 93:298-301 (Abstract)
16. Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B (1998) Lipoprotein receptors in acute myelogenous leukemia: Failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am J Pathol 153:1923-1935
17. Tatidis L, Vitols S, Bruber A, Paul C, Axelson M (2001) Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: Suppressed levels of circulating marker for bile acid synthesis. Cancer Letters 170:169-175
18. Aviram M, Brook JG, Tatarsky I, Levy Y, Carter A (1986) Increased low density lipoprotein levels after splenectomy: A role for the spleen in cholesterol metabolism in myeloproliferative disorders. Am J Med Sci 29:25-28
19. Dispenzeri A, Lacy MQ, Greipp PR (2004) Multiple myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds) Wintrobe's clinical hematology, 11st edn. Lippincott Williams-Wilkins, Philadelphia, pp 2583-2636
20. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Baccadora M (2004) New drugs for treatment of multiple myeloma. Lancet Oncol 5:430-442
21. Li JL, Li YJ, Chao YJ, Lin LX, Ouyang MH, Peng YB, Chang WS (1991) Cholesterol requirement for growth of Ir983f and P3x63-Ag8-U1 myeloma cells in serum-free medium. Cytobios 68:15-22
22. Sato JD, Kawamoto T, Okamoto T (1987) Cholesterol requirement of P3-X63-Ag8 and X63-Ag8.653 mouse myeloma cells for growth in vitro. J Exp Med 165:1761-1766
23. Aixala M, Sarandria CN, Speroni JG (1997) Hypocholesterolemia in hematologic neoplasms. Sangre 42:7-10 (Abstract)
24. Scolozzi R, Boccafogli A, Salmi R, Furlani MR, Guidoboni CA, Vicentini L, Coletti M, Tocchetto M (1983) Hypocholesterolemia in multiple myeloma. Inverse relation to the component M and the clinical stage. Minerva Med 74:2359-2364 (Abstract)
25. Hachem H, Favre G, Ghalim N, Puchois P, Fruchart JC, Soula G (1987) Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 25:675-679
26. Levy Y, Aviram M, Spira G, Tatarsky I, Brook GJ, Carter A (1984) Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies. Postgraduate Med J 60:449-453
27. Van De Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362-1371
28. Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, Lishner M (2004) Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52:335-344
29. Van Der Spek E, Bloem AC, Van De Donk NW, Rogers LH, Van Der Griend R, Kramer MH, De Weerdt O, Wittebol S, Lokhorst HM (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91:542-545
30. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group. Br J Haematol 121:749-757
31. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842-854
32. Friedewald WT, Levy RI, Fredrikson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:449-502
33. Mahley RW, Weisgraber KH, Farese RV (1998) Disorders of lipid metabolism. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds) Williams textbook of endocrinology, 9th edn. Saunders, Philadelphia, pp 1099-1153
34. Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhao RC (2004) Metabolism of a cholesterol-rich microemulsion (Lde) in patients with multiple myeloma and a preliminary clinical study of Lde as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53:51-60
35. Tsuchiya J (1989) Some problems in the laboratory findings in multiple myeloma. Nippon Ketsueki Gakkai Zasshi 52:1273-1278 (Abstract)
36. Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M (2004) Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 73:183-190
37. Van De Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem EC (2005) Geranylgeranylated proteins are involvedin the regulation of myeloma cell growth. Clin Cancer Res 11:429-439
38. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini E (2000) Non-lipid related effects of statins. Ann Med 32:164-176
39. Thibault A, Samid D, Tompkins AC, Wigg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer. Clin Cancer Res 2:483-491
40. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81-83